KALV - Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval Aiming For 2025 Launch

2024-06-24 02:53:53 ET

Summary

• KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa.
• Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches.
• KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise.
• Sebetralstat could capture the $900 million on-demand HAE market and enhance its TAM to the $2.9 billion HAE market.
• Despite recent equity dilution, I believe KalVista's financials and regulatory progress make it a "buy" for new investors aware of biotech risks.

...

For further details see: